ArticleBlood cancer journal2026

Final analysis results from DREAMM-3, a phase 3 study of belantamab mafodotin versus pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Meletios Athanasios Dimopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.